Insight in United Kingdom

Published within

« | ... | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | ... | » »|

Type Product title / description Pub Price
Report
Report

Forecast Insight: Antihypertensives - Fixed-dose combinations fail to offset generic erosion

Commercial analysis of the antihypertensive markets in the US, Japan, France, Germany, Italy, Spain, and the UK. Volume and revenue sales forecast to 2019.

Published By Datamonitor
08 Dec 2010 $6400
Buy
Report
Report

Forecast Insight: Depression - High rewards for novel and adjunctive therapies in treatment-resistant depression

Analysis of the current and future market for drugs treating depression. Includes sales forecasts to 2019 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) of key marketed brands, generics, and pipeline products.

Published By Datamonitor
09 Dec 2010 $6400
Buy
Report
Report

Pipeline Insight: Lung Cancers Overview – Intensive R&D activity but little improvement in patient outcomes

Overview of the current lung cancers clinical pipeline, including in-depth analysis of late-phase products, clinical trial data, sales forecasts through to 2019, Datamonitor drug assessment summaries and key opinion leader insight.

Published By Datamonitor
10 Dec 2010 $3600
Buy
Report
Report

Pipeline Insight: Cancer Overview Malignant Melanoma, Neuroendocrine Tumors and Thyroid Cancer - New drug approvals likely after decades of little progress

Overview of the current melanoma, thyroid cancer and neuroendocrine tumor pipelines, including in-depth analysis of late-phase products, sales forecasts through to 2019, Datamonitor drug assessment summaries and key opinion leader insight.

Published By Datamonitor
10 Dec 2010 $3600
Buy
Report
Report

Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.

In-depth review of non-insulin developmental products for the treatment of diabetes, including an assessment of the commercial prospects of late-stage drugs, unmet market needs and sales forecasts to 2019.

Published By Datamonitor
10 Dec 2010 $11400
Buy
Report
Report

Pipeline and Commercial Insight: Psoriasis - Established brands challenged by new therapies

Overview of the current and future psoriasis market, providing in-depth analysis of recent events in the market together with 10 year indication specific sales forecasts and profiles of key brands and pipeline products across the seven major markets.

Published By Datamonitor
10 Dec 2010 $6400
Buy
Report
Report

Epidemiology: Type 1 diabetes - There will be an increasing number of new cases of type 1 diabetes in the seven major markets in the coming decade

Overview of type 1 diabetes definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year incident case forecast, and prevalent cases for 2010 across the seven major markets.

Published By Datamonitor
12 Dec 2010 $2800
Buy
Report
Report

Epidemiology: Hepatocellular Cancer - Hepatocellular cancer is a common cancer worldwide and incidence is increasing in the US and Europe

Overview of hepatocellular cancer definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year incident case forecast, and key patient segments across the seven major markets.

Published By Datamonitor
12 Dec 2010 $2800
Buy
Report
Report

Epidemiology: Gastric Cancer - Gastric cancer is the fourth most common cancer in the seven major markets and the number of incident cases will continue to decline throughout the forecast period

Overview of gastric cancer definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year incident case forecast, and key patient segments across the seven major markets.

Published By Datamonitor
13 Dec 2010 $2800
Buy
Brief
Brief

Brief: Hepatitis C/AASLD 2010

This brief is an overview of the HCV highlights from the 2010 American Association of the Study of Liver Disease meeting. It discusses pivotal data for telaprevir and boceprevir, results for TMC435 and data from interferon-sparing studies.

Published By Datamonitor
13 Dec 2010 $400
Buy

« | ... | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | ... | » »|

No help is available.